CCNB1IP1 Antibody

Definition and Functional Context of CCNB1IP1 Antibody

CCNB1IP1 antibodies are monoclonal or polyclonal reagents designed to detect and quantify CCNB1IP1 protein levels in experimental models. These antibodies enable researchers to study CCNB1IP1's roles in:

• Cell cycle regulation: Interaction with cyclin B1 and modulation of G2/M phase transitions .

• Ubiquitination pathways: Stabilization of oncoproteins like MYCN by competing with E3 ligases such as FBXW7 .

• Cancer biology: Dysregulation in neuroblastoma (NB), melanoma, and hepatocellular carcinoma .

Neuroblastoma Studies

CCNB1IP1 antibodies have been critical in elucidating its oncogenic partnership with MYCN in MYCN-amplified NB:

• Mechanistic insights: CCNB1IP1 stabilizes MYCN by blocking FBXW7-mediated ubiquitination, forming a positive feedback loop .

• Therapeutic targeting: Silencing CCNB1IP1 reduces NB cell proliferation and tumorigenicity in vivo .

Meiotic Regulation

In meiosis, CCNB1IP1 antibodies identified its role in SUMOylation and crossover formation:

• SUMO E3 ligase activity: CCNB1IP1 mediates SUMO modification of proteins essential for crossover maturation .

Cancer Heterogeneity

Antibody-based assays revealed contradictory expression patterns:

• Overexpression: Observed in NB, melanoma, and hepatocellular carcinoma .

• Underexpression: Reported in colon, breast, and non-small cell lung cancers .

Research Protocols Utilizing CCNB1IP1 Antibody

• Immunofluorescence (IF): Used to visualize CCNB1IP1-MYCN co-localization in NB cells .

• Chromatin Immunoprecipitation (CHIP): Confirmed MYCN binds the CCNB1IP1 promoter .

• Co-Immunoprecipitation (Co-IP): Demonstrated CCNB1IP1-FBXW7 competition for MYCN .

Limitations and Future Directions

• Antibody specificity: Variability in epitope recognition across isoforms requires validation .

• Clinical translation: Further in vivo studies are needed to assess blockade efficacy .